Merrimack pharmaceuticals inc (MACK)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Jun'11Mar'11
Cash flows from operating activities
Net income (loss)

-6,625

-17,332

-29,537

-24,843

-33,182

-40,506

-44,513

-45,369

483,239

470,868

450,192

416,784

-145,013

-153,518

-167,958

-180,069

-152,013

-147,787

-109,197

-94,849

-90,237

-83,559

-106,430

-118,155

-130,116

-130,685

-123,230

-106,787

-96,675

-91,754

0

0

0

0

0

Income from discontinued operations

-

-

-

-

-

-

-

-

-

546,872

554,458

542,572

2,762

2,766

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-76,004

-104,266

-125,788

-147,775

-156,284

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Adjustments to reconcile net income (loss) to net cash used in operating activities
Non-cash interest expense

-

141

0

0

0

-

-

-

-

3,678

4,684

4,873

5,322

6,004

6,758

7,684

8,470

8,217

8,249

8,282

8,304

8,511

8,600

8,345

6,458

4,548

0

0

0

-

-

-

-

-

-

Remeasurement of convertible preferred stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

Remeasurement of convertible preferred stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Amortization of deferred lease benefits and tax incentives

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Depreciation and amortization expense

-

2,228

3,091

4,044

4,054

4,074

5,619

5,421

5,278

5,221

3,527

4,620

4,879

4,895

3,111

3,491

3,394

3,250

3,947

2,289

2,606

2,438

3,474

3,511

2,775

2,589

2,647

2,720

3,163

3,664

0

0

0

0

0

Gain on sale of property and equipment

-

1,984

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of in progress research and development

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Premiums paid on marketable securities

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization and accretion on marketable securities

-

292

545

707

726

651

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

2,261

2,371

2,508

2,587

2,880

3,050

4,004

4,803

12,756

12,788

14,999

15,592

10,426

12,140

9,385

10,901

12,301

13,161

14,064

13,224

12,412

11,978

12,721

12,408

11,283

10,733

0

0

0

-

-

-

-

-

-

Loss on equity method investment

-

372

-1,093

-1,334

-2,678

-3,123

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchased premiums and interest on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-158

1,522

1,519

1,809

0

0

0

-

-

-

-

-

-

Stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

264

-403

46

-2,600

-1,654

-1,367

-6,694

-9,598

-4,235

-7,108

-7,932

2,357

-3,410

2,781

7,597

3,818

1,841

0

0

0

0

0

Prepaid expenses and other assets

-4,286

-3,917

-2,322

-1,518

1,977

993

2,670

4,765

7,303

8,476

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Accounts payable, accrued expenses and other

-7,410

-12,081

-14,996

-11,619

-5,860

-3,801

-5,055

-13,809

-19,729

-9,278

-8,916

1,111

448

-9,837

8,767

-2,765

6,283

13,163

-3,229

7,860

3,557

-5,641

-8,514

-4,109

1,845

13,304

26,707

19,024

16,251

6,985

0

0

0

-

-

Deferred rent

-

-

-

-

-

-2,262

-3,391

-2,867

-2,453

-2,021

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Accrued expenses and other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Deferred revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-148,840

-73,725

-83,776

-73,392

49,275

-28,754

-3,762

-4,989

-8,018

-8,238

-11,708

-5,281

0

0

0

0

0

Deferred lease benefits and tax incentives

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Other assets and liabilities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

-

2,822

313

-3,335

-1,032

-1,066

-1,440

-188

1,030

0

0

0

0

0

Net cash used in continuing operations for operating activities

-

-

-

-

-

-

-

-

-

-84,146

-99,186

-82,007

-108,346

-122,935

-94,586

-120,069

-107,462

-109,828

-195,216

-91,728

-99,983

-96,291

-30,548

-113,965

-105,366

-95,175

-87,184

-84,804

-81,609

-79,816

0

0

0

0

0

Net cash used in discontinued operations for operating activities

-

-

-

-

-

-

-

-

-

-41,665

-32,732

-59,194

-18,528

-47,306

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-18,721

-31,368

-47,620

-57,531

-61,901

-65,588

-71,486

-84,007

-132,994

-125,811

-131,918

-141,201

-126,874

-170,241

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities
Proceeds on sale of property and equipment

-

2,025

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

-

-

-

-

-

118

304

746

641

915

501

877

1,701

2,640

6,643

9,847

11,927

11,902

7,951

5,660

4,304

4,538

5,510

9,535

8,941

9,857

10,826

5,603

5,217

3,189

0

0

0

0

0

Proceeds from sale of in progress research and development

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of marketable securities

-

-

-

-

-

103,055

0

0

0

-

-

-

-

-

-

-

0

-

-

-

-

111,832

105,158

124,733

110,933

112,923

0

0

0

-

-

-

-

-

-

Proceeds from maturities and sales of marketable securities

-

51,500

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

87,899

87,024

71,088

99,419

111,858

127,693

140,823

111,752

95,100

0

0

0

-

-

-

-

-

-

Other investing activities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Net cash provided by (used in) continuing operations for investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

75,997

38,173

-26,306

-11,619

-4,514

17,022

6,535

-8,181

-27,739

-29,048

36,971

-63,289

-75,221

0

0

0

0

0

Net cash provided by investing activities

42,160

69,825

54,002

73,126

49,351

-22,598

-6,247

-36,325

535,347

576,891

583,076

635,872

81,944

-3,257

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities
Proceeds from exercise of options

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of options and warrants to purchase common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,087

12,098

11,990

11,386

10,384

-19,654

5,768

3,971

2,036

0

0

0

-

-

-

-

-

-

Proceeds from at the market offering, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Proceeds from issuance of preferred stock by Silver Creek Pharmaceuticals, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,083

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Other financing activities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-195

382

-48

0

0

0

-

-

Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payment on capital lease obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

180,164

53,084

13,961

13,552

11,421

8,398

154,238

152,009

150,286

193,774

46,733

142,778

142,297

0

0

0

0

0

Net increase in cash, cash equivalents and restricted cash

-19,101

-4,083

-29,520

14,265

2,082

-73,554

-117,651

-173,049

17,113

71,917

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-164,082

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-38,064

-

-5,128

46,808

38,462

27,372

77,542

-1,100

-2,120

-12,740

0

0

0

0

0

Purchases of property and equipment in accounts payable, accrued expenses and other

-

-

-

-

-

-

-

-

94

14

184

45

-224

130

-879

-810

27

816

0

0

0

-

-

-

-

-

-

-

0

-

-

-

-

-

-

Receivables related to stock option exercises in prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

232

-34

-133

-133

14

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivables related to property and equipment sale in other current assets

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in deferred financing costs included in ending accounts payable, accrued expenses and other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Issuance of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

35

0

0

0

-

-

-

-

-

-

Disposals of fully-depreciated property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,672

803

569

210

0

0

0

-

-

-

-

-

-

Supplemental disclosure of cash flows
Cash paid for income taxes

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

1,400

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

9,032

10,087

9,541

9,541

9,542

9,510

9,872

6,754

6,753

3,915

0

0

0

-

-

-

-

0

0